

J Fraser Wright

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9721775/publications.pdf>

Version: 2024-02-01

29
papers

7,375
citations

279798

23
h-index

477307

29
g-index

30
all docs

30
docs citations

30
times ranked

9058
citing authors

#	ARTICLE	IF	CITATIONS
1	Chimeric Antigen Receptorâ€“Modified T Cells for Acute Lymphoid Leukemia. <i>New England Journal of Medicine</i> , 2013, 368, 1509-1518.	27.0	3,021
2	Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. <i>Nature Medicine</i> , 2006, 12, 342-347.	30.7	1,865
3	Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. <i>New England Journal of Medicine</i> , 2017, 377, 2215-2227.	27.0	549
4	Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. <i>Lancet</i> , The, 2016, 388, 661-672.	13.7	377
5	Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutationâ€“Associated Inherited Retinal Dystrophy. <i>Ophthalmology</i> , 2019, 126, 1273-1285.	5.2	239
6	Assessing the potential for AAV vector genotoxicity in a murine model. <i>Blood</i> , 2011, 117, 3311-3319.	1.4	196
7	Retinal AAV8-RS1 Gene Therapy for X-Linked Retinoschisis: Initial Findings from a Phase I/IIa Trial by Intravitreal Delivery. <i>Molecular Therapy</i> , 2018, 26, 2282-2294.	8.2	173
8	Product-Related Impurities in Clinical-Grade Recombinant AAV Vectors: Characterization and Risk Assessment. <i>Biomedicines</i> , 2014, 2, 80-97.	3.2	115
9	Transient Transfection Methods for Clinical Adeno-Associated Viral Vector Production. <i>Human Gene Therapy</i> , 2009, 20, 698-706.	2.7	112
10	Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial. <i>Lancet HIV</i> , the, 2019, 6, e230-e239.	4.7	84
11	Development of Î²-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	82
12	Undetectable Transcription of cap in a Clinical AAV Vector: Implications for Preformed Capsid in Immune Responses. <i>Molecular Therapy</i> , 2009, 17, 144-152.	8.2	80
13	AAV Empty Capsids: For Better or for Worse?. <i>Molecular Therapy</i> , 2014, 22, 1-2.	8.2	71
14	Codon Modification and PAMPs in Clinical AAV Vectors: The Tortoise or the Hare?. <i>Molecular Therapy</i> , 2020, 28, 701-703.	8.2	48
15	Quality Control Testing, Characterization and Critical Quality Attributes of Adenoâ€“Associated Virus Vectors Used for Human Gene Therapy. <i>Biotechnology Journal</i> , 2021, 16, e2000022.	3.5	48
16	Challenges Posed by Immune Responses to AAV Vectors: Addressing Root Causes. <i>Frontiers in Immunology</i> , 2021, 12, 675897.	4.8	46
17	Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery. <i>Molecular Therapy - Methods and Clinical Development</i> , 2014, 1, 14036.	4.1	35
18	Timing of Intensive Immunosuppression Impacts Risk of Transgene Antibodies after AAV Gene Therapy in Nonhuman Primates. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 17, 1129-1138.	4.1	34

#	ARTICLE	IF	CITATIONS
19	Manufacturing and Regulatory Strategies for Clinical AAV2-hRPE65. <i>Current Gene Therapy</i> , 2010, 10, 341-349.	2.0	33
20	Quantification of CpG Motifs in rAAV Genomes: Avoiding the Toll. <i>Molecular Therapy</i> , 2020, 28, 1756-1758.	8.2	29
21	Effects of FVIII immunity on hepatocyte and hematopoietic stem cell-directed gene therapy of murine hemophilia A. <i>Molecular Therapy - Methods and Clinical Development</i> , 2016, 3, 15056.	4.1	26
22	Safety and tolerability of MRI-guided infusion of AAV2-hAADC into the mid-brain of nonhuman primate. <i>Molecular Therapy - Methods and Clinical Development</i> , 2014, 1, 14049.	4.1	24
23	Preclinical Potency and Biodistribution Studies of an AAV 5 Vector Expressing Human Interferon- γ^2 (ART-I02) for Local Treatment of Patients with Rheumatoid Arthritis. <i>PLoS ONE</i> , 2015, 10, e0130612.	2.5	24
24	Vector Characterization Methods for Quality Control Testing of Recombinant Adeno-Associated Viruses. <i>Methods in Molecular Biology</i> , 2011, 737, 247-278.	0.9	23
25	Safety, Biodistribution, and Efficacy of an AAV-5 Vector Encoding Human Interferon-Beta (ART-I02) Delivered via Intra-Articular Injection in Rhesus Monkeys with Collagen-Induced Arthritis. <i>Human Gene Therapy Clinical Development</i> , 2015, 26, 103-112.	3.1	17
26	New Adeno-Associated Virus Strategies to Support Momentum in the Clinic. <i>Human Gene Therapy</i> , 2011, 22, 519-521.	2.7	9
27	Bioengineered Coagulation Factor VIII Enables Long-Term Correction Of Murine Hemophilia A Following Liver-Directed Adeno-Associated Viral Vector Delivery. <i>Blood</i> , 2013, 122, 4210-4210.	1.4	9
28	Recombinant Adeno-Associated Virus Quality Control for Non-Clinical and Clinical Vectors: How an Unregulated Commercial Sector Can Compromise Development of New Gene Therapies. <i>Human Gene Therapy</i> , 2019, 30, 1447-1448.	2.7	3
29	Design of experiments as a decision tool for cell therapy manufacturing. <i>Cytotherapy</i> , 2022, 24, 590-596.	0.7	3